Article
Apigenin is a promising molecule for treatment of visceral leishmaniasis
Registro en:
EMILIANO, Yago S. S. ; AMARAL, Elmo E. Almeida. Apigenin is a promising molecule for treatment of visceral leishmaniasis. Front. Cell. Infect. Microbiol v. 13:1066407, p. 1 - 6, Apr. 2023.
2235-2988
10.3389/fcimb.2023.1066407
Autor
Emiliano, Yago S. S.
Amaral, Elmo E. Almeida
Resumen
Current treatment for visceral leishmaniasis is based on drugs such as
pentavalent antimony and amphotericin B. However, this treatment remains
mostly ineffective and expensive, resulting in several side effects and generating
resistance. Apigenin, a flavonoid present in fruits and vegetables, has
demonstrated several biological functions. In the present study, we observed a
concentration-dependent inhibition of the L. infantum promastigote in the
presence of apigenin, exhibiting an IC50 value of 29.9 μM. Its effect was also
evaluated in L. infantum-infected murine peritoneal macrophages, presenting an
C50 value against intracellular amastigotes of 2.3 μM and a selectivity index of
34.3. In a murine model of visceral leishmaniasis, the in vivo effect of apigenin
was measured using short-term and long-term treatment schemes. Treatment
with apigenin demonstrated 99.7% and 94% reductions in the liver parasite load
in the short-term and long-term treatment schemes, respectively. Furthermore,
no alterations in serological and hematological parameters were observed.
Taken together, these results suggest that apigenin is a potential candidate for
visceral leishmaniasis chemotherapy by oral administration.